| Literature DB >> 32868231 |
Valeria D'Ovidio1, Cristina Lucidi2, Giovanni Bruno2, Daniele Lisi2, Lucia Miglioresi2, Marco Emilio Bazuro2.
Abstract
INTRODUCTION: One of the main clusters of coronavirus disease-2019 (COVID-19) has been identified in Italy. Following European and local guidelines, Italian endoscopy units modulated their activity. We aimed at analyzing the need and safety to continue selective colorectal cancer screening (CRCS) colonoscopies during the COVID-19 pandemic. PATIENTS AND METHODS: We carried out a retrospective controlled cohort study in our "COVID-free" hospital to compare data of the CRCS colonoscopies of the lockdown period (March 9 to May 4, 2020) with those of the same period of 2019 (control group). A pre/post endoscopic sanitary surveillance for COVID-19 infection was organized for patients and sanitary staff.Entities:
Keywords: Adenoma; Colonoscopy; Endoscopy; Lockdown; Neoplastic; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32868231 PMCID: PMC7391078 DOI: 10.1016/j.clcc.2020.07.006
Source DB: PubMed Journal: Clin Colorectal Cancer ISSN: 1533-0028 Impact factor: 4.481
Figure 1Total Cases of COVID-19 Infections Registered in Italy on March 9, 2020
Baseline Demographic and Clinical Characteristics of the 2 Cohorts of Patients
| Lockdown Group (n = 60), n (%) | Control Group (n = 238), n (%) | ||
|---|---|---|---|
| Gender (M/F), n (% of male) | 26/34 (43) | 131/107 (55) | NS (.1) |
| Age, y | 59 ± 8.2 | 65 ± 7 | NS (.2) |
| Invitation indication | |||
| FIT | 51 (85) | 213 (89) | |
| Polypectomy surveillance | 4 (7) | 12 (5) | NS (.3) |
| Familiar surveillance | 5 (9) | 14 (6) | |
| Reported familiarity | 22 (36) | 49 (20) | .008 |
| Relevant symptoms | 11 (18) | 19 (8) | .02 |
Abbreviations: F = female; FIT = fecal immunochemical test; M = male; NS = not significant.
Histopathologic Findings of the 2 Cohorts of Patients
| Lockdown Group (n = 60), n (%) | Control Group (n = 238), n (%) | ||
|---|---|---|---|
| Colorectal cancer | |||
| Any stage | 5 (8) | 3 (1) | .002 |
| Stage > 1 | 3 (5) | 3 (1) | .06 |
| Adenoma detection rate | 34 (57) | 113 (47.5) | NS (.2) |
| High-risk adenoma detection rate | 28 (47) | 60 (25) | .001 |
| High-risk variables | |||
| Adenoma > 10 mm | 24 (40) | 31 (13) | <.0001 |
| >3 adenomas | 10 (17) | 24 (10) | .15 |
| High-grade dysplasia | 15 (25) | 15 (6) | <.0001 |
| Villous component | 13 (22) | 27 (11) | .03 |
| Serrated | 4 (7) | 2 (1) | .004 |
| Mean adenoma size, mm | 12.8 ± 2.2 | 8.5 ± 6.9 | <.001 |
| Mean high risk adenoma size, mm | 21 ± 12.5 | 11.6 ± 8.4 | <.001 |
Abbreviation: NS = not significant.
Figure 2Comparison of Detected Lesions in Lockdown Group (March 9 to May 4, 2020, COVID-19 Period) (A) and Control Group (Same Period 2019) (B). Total CRCS Colonoscopies in Lockdown Group Versus Control Group (n = 60 vs. n = 238). High-Risk and Low-Risk Superficial Neoplastic Lesions Were Classified according to European Society of Gastrointestinal Endoscopy Guidelines
Abbreviation: CRCS = colorectal cancer screening.
Logistic Regression Analysis of Independent Predictive Factors of High-risk Colorectal Lesions (High-risk Adenomas and Colorectal Cancers)
| Hazard Ratio | Confidence Interval | ||
|---|---|---|---|
| Reported colorectal cancer familiarity | .02 | 1.99 | 1.1-3.6 |
| Relevant symptoms | .006 | 3.1 | 1.4-6.8 |
| Lockdown period | .01 | 2.2 | 1.2-4 |